

ASX Announcement  
08 August 2024

## **Tony Charara Co-founder appointed as CEO of TRP**

---

Tissue Repair Limited (ASX:TRP) (the Company) advises that Tony Charara has been appointed as the CEO. Mr Charara was the founder of TRP and is currently TRP's Executive Director.

The Board believes the change in title reflects more accurately Mr Charara's role in the Company since listing.

The Board believes it has become appropriate to make this change as TRP prepares to commence its planned Phase 3 trials for its TR-987® drug candidate for chronic wounds and sales growth of its TR Pro+™ product for cosmetic and medical procedures starts to accelerate.

| <b>Key Terms and Conditions of Employment Agreement</b> |  |
|---|--|
| Commencement Date                                       | Immediate  |
| Term  | No fixed term  |
| Fixed Remuneration (FR)                                 | No change from Existing Executive Service Agreement  |
| Short Term Incentives (STI)                             | The CEO can earn an STI of up to 20% of his FR for the year to June 30th 2025 subject to a range of performance hurdles related to execution of the TR-987® clinical trials and sales growth for TR Pro+™. Future STIs will be based on the short term objectives of the company in each year ahead. |
| Long Term Incentives                                    | The grant of 750,000 options under the TRP LTIP exercisable at a price of \$1.15 (current market price \$0.35).<br>This grant will be subject to shareholder approval at the Company's next AGM. The options will vest in equal monthly tranches over the 36 months following shareholder approval   |
| Termination and Notice                                  | Three months on each side  |

For further information in relation to this release please contact Dominique Peters-Kelly at [assist@trtherapeutics.com](mailto:assist@trtherapeutics.com)

*This announcement has been approved for release by TRP's Board.*

### **About Tissue Repair**

Tissue Repair Limited (ASX:TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company is a Phase 3 asset and is focusing on commencing phase 3 trials in chronic wounds for its lead drug candidate TR-987®, with a secondary focus on commercialising TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds, skin and aesthetic conditions.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566